ผู้ทำคำเสนอซื้อ : ASAHI GLASS CO., LTD. | วันที่ยื่นแบบประกาศเจตนา : 17/04/2544
of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27 Notification of the resignation of Chairman of the Audit
Committee, Appointment of Audit Committee, Appointment of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27
the issuer’s core business. In any event, the issuer must not operate business in such a way that involves severely illegal business. For example, human trafficking, drug production or smuggling, or
involves severely illegal business. For example, human trafficking, drug smuggling or money laundering etc. Moreover, the issuer must not act in violation or non-compliance with the law, which may cause
>คณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์
counterparty, and include terms for the future sale of SDA shares of SUSCO wherein Sinopec must be granted tag-along rights. This results in reduced flexibility and adaptability in SUSCO’s future management
ธุรกิจใหม่ ๆ ของ SUSCO ซึ่งเงื่อนไขดังกล่าวบังคับใช้กับ SUSCO เพียงฝ่ายเดียว ไม่บังคับใช้กับคู่สัญญา และมีเงื่อนไขการขายหุ้น SDA ของ SUSCO ในอนาคต โดย Sinopec ต้องได้สิทธิในการร่วมขายหุ้น (tag-along
system of new medicines according to the additional standards SET forth by the Food and Drug administration. Therefore, it is necessary to use the capital to proceed the project amount 32,000,000 baht
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including